Hikma Pharma tumbles on softer guidance as buyback fails to soften pill

Hikma Pharma tumbles on softer guidance as buyback fails to soften pill Proactive uses images sourced from Shutterstock Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026. Executive chair Said Darwazah will become full-time chief executive for the next two years, with current chief financial officer Khalid Nabilsi becoming deputy chief executive with responsibility f ...